J Cabeza Barrera

934 total citations
60 papers, 657 citations indexed

About

J Cabeza Barrera is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, J Cabeza Barrera has authored 60 papers receiving a total of 657 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 14 papers in Oncology and 12 papers in Immunology. Recurrent topics in J Cabeza Barrera's work include Protein purification and stability (13 papers), Biosimilars and Bioanalytical Methods (10 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). J Cabeza Barrera is often cited by papers focused on Protein purification and stability (13 papers), Biosimilars and Bioanalytical Methods (10 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). J Cabeza Barrera collaborates with scholars based in Spain, United States and United Kingdom. J Cabeza Barrera's co-authors include Antonio Salmerón‐García, Natalia Navas, Cristina Lucía Dávila-Fajardo, Luis Cuadros-Rodrı́guez, Antonio Jesús Martínez-Ortega, L.F. Capitán‐Vallvey, Luis Javier Martínez-González, Rocío Morón, Manuel Colmenero and Maria Elena Rodríguez‐Cabezas and has published in prestigious journals such as PLoS ONE, Scientific Reports and Nutrients.

In The Last Decade

J Cabeza Barrera

55 papers receiving 644 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J Cabeza Barrera Spain 16 260 132 131 100 86 60 657
Carlos Alves Portugal 18 193 0.7× 66 0.5× 166 1.3× 73 0.7× 62 0.7× 54 1.2k
Chandrahas Sahajwalla United States 14 151 0.6× 95 0.7× 88 0.7× 99 1.0× 30 0.3× 44 771
Songmao Zheng United States 15 190 0.7× 105 0.8× 154 1.2× 150 1.5× 22 0.3× 35 762
G. Aulagner France 18 126 0.5× 239 1.8× 119 0.9× 49 0.5× 52 0.6× 79 1.2k
Estelle Marrer Switzerland 11 236 0.9× 35 0.3× 83 0.6× 69 0.7× 60 0.7× 13 885
Christian Laveille France 14 120 0.5× 43 0.3× 117 0.9× 118 1.2× 152 1.8× 33 1.0k
Martin Czejka Austria 15 158 0.6× 67 0.5× 245 1.9× 35 0.3× 42 0.5× 70 739
Maurizio Biselli Italy 21 144 0.6× 78 0.6× 155 1.2× 79 0.8× 52 0.6× 53 1.6k
Chengxian Guo China 18 237 0.9× 60 0.5× 171 1.3× 31 0.3× 42 0.5× 76 804
John Mondick United States 15 101 0.4× 55 0.4× 61 0.5× 59 0.6× 40 0.5× 32 598

Countries citing papers authored by J Cabeza Barrera

Since Specialization
Citations

This map shows the geographic impact of J Cabeza Barrera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Cabeza Barrera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Cabeza Barrera more than expected).

Fields of papers citing papers by J Cabeza Barrera

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Cabeza Barrera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Cabeza Barrera. The network helps show where J Cabeza Barrera may publish in the future.

Co-authorship network of co-authors of J Cabeza Barrera

This figure shows the co-authorship network connecting the top 25 collaborators of J Cabeza Barrera. A scholar is included among the top collaborators of J Cabeza Barrera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J Cabeza Barrera. J Cabeza Barrera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Díaz-Villamarín, Xando, María Jesús Martínez-Pérez, Emilio Fernández-Varón, et al.. (2025). Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review. Pharmaceutics. 17(5). 542–542. 1 indexed citations
2.
Díaz-Villamarín, Xando, María Jesús Martínez-Pérez, Emilio Fernández-Varón, et al.. (2025). Clinical Pharmacogenetics: Results After Implementation of Preemptive Tests in Daily Routine. Journal of Personalized Medicine. 15(6). 245–245. 1 indexed citations
3.
4.
Caballero, Teresa, Carmen Alonso, M. L. Baeza, et al.. (2024). Hereditary angioedema in Spain: medical care and patient journey. Orphanet Journal of Rare Diseases. 19(1). 210–210.
5.
Salmerón‐García, Antonio, et al.. (2024). Comprehensive Analysis of Cetuximab Critical Quality Attributes: Impact of Handling on Antigen-Antibody Binding. Pharmaceutics. 16(9). 1222–1222.
6.
Martínez-Pérez, María Jesús, Rocío Morón, Xando Díaz-Villamarín, et al.. (2024). Selective Digestive Decontamination: A Comprehensive Approach to Reducing Nosocomial Infections and Antimicrobial Resistance in the ICU. Journal of Clinical Medicine. 13(21). 6482–6482. 3 indexed citations
7.
Salmerón‐García, Antonio, et al.. (2023). Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate. Vaccines. 11(11). 1635–1635. 17 indexed citations
8.
Diez‐Echave, Patricia, Natalia Chueca, Féderico García, et al.. (2023). Gut Microbiota Composition Can Predict Colonization by Multidrug-Resistant Bacteria in SARS-CoV-2 Patients in Intensive Care Unit: A Pilot Study. Antibiotics. 12(3). 498–498. 6 indexed citations
9.
Salmerón‐García, Antonio, et al.. (2023). Comprehensive physicochemical and functional analysis of pembrolizumab based on controlled degradation studies: Impact on antigen–antibody binding. European Journal of Pharmaceutics and Biopharmaceutics. 194. 131–147. 3 indexed citations
10.
Salmerón‐García, Antonio, et al.. (2022). Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress. Pharmaceutics. 14(4). 692–692. 13 indexed citations
11.
Navas, Natalia, et al.. (2021). The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. Vaccines. 9(6). 557–557. 13 indexed citations
12.
Salmerón‐García, Antonio, et al.. (2020). Comprehensive biophysical and functional study of ziv-aflibercept: characterization and forced degradation. Scientific Reports. 10(1). 2675–2675. 14 indexed citations
13.
Pérez-Ramírez, Cristina, Marisa Cañadas‐Garre, Miguel Ángel Molina‐Vila, J Cabeza Barrera, & María José Faus-Dáder. (2019). Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients. Mutation Research/Reviews in Mutation Research. 781. 63–70. 10 indexed citations
14.
15.
Martínez-Ortega, Antonio Jesús, Antonio Salmerón‐García, J Cabeza Barrera, et al.. (2018). Study of aggregation in therapeutic monoclonal antibodies subjected to stress and long-term stability tests by analyzing size exclusion liquid chromatographic profiles. International Journal of Biological Macromolecules. 118(Pt A). 511–524. 24 indexed citations
16.
Barrera, J Cabeza, et al.. (2018). Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane. Anti-Cancer Drugs. 29(9). 821–826. 6 indexed citations
17.
López-Sepúlveda, R, et al.. (2017). Antidiabetic medications use trends in an Andalusian region from 2001 to 2014. Primary care diabetes. 11(3). 254–264. 6 indexed citations
18.
19.
Barrera, J Cabeza, et al.. (2000). Adecuacion de las formas de dosificacion de los farmacos antiretrovirales como metodo de mejora del cumplimiento de los pacientes de VIH-SIDA. 2(1). 85–91. 1 indexed citations
20.
Barrera, J Cabeza, et al.. (1999). INTERVENCIÓN PARA MEJORAR LA CALIDAD DE LA PRESCRIPCIÓN DE ANTIBACTERIANOS EN ATENCIÓN PRIMARIA. Farmacia Hospitalaria. 23(1). 42–47. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carlos Alves Breakdown of academic impact, for papers by Chandrahas Sahajwalla Breakdown of academic impact, for papers by Songmao Zheng Breakdown of academic impact, for papers by G. Aulagner Breakdown of academic impact, for papers by Estelle Marrer Breakdown of academic impact, for papers by Christian Laveille Breakdown of academic impact, for papers by Martin Czejka Breakdown of academic impact, for papers by Maurizio Biselli Breakdown of academic impact, for papers by Chengxian Guo Breakdown of academic impact, for papers by John Mondick
Rankless by CCL
2026